Desk›Healthcare› Nephrocare Health Services Ltd
Nephrocare Health Services Ltd
BSE 544647 · NSE NEPHROPLUS · ISIN INE428V01029 · Group B · Active
Healthcare › Healthcare › Healthcare Services › Healthcare Service Provider
₹691.80
+1.15%
BSE close, 28 August 2026
₹6,956.67 cr
10.1 cr shares · Small cap
₹2,494.07 cr
as published
— · —
EPS — · BV —
629.74 / -8.06
₹ cr, as filed
27
10 selected · 37%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -9.9% |
|---|---|
| Against 52-week low | +55.5% |
| Day change | +1.15% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | — |
|---|---|
| Price / earnings | — |
| Price / book | — |
| Book value — derived, price ÷ P/B | — |
| Return on equity | — |
| Operating margin | 17.76% |
| Net margin | 7.37% |
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 170.38 | 12.56 | 1.25 | 17.76% | 7.37% |
| Mar-26 · Q | 164.33 | 10.89 | 1.09 | 17.17% | 6.63% |
| FY25-26 | 629.74 | -8.06 | -0.89 | 16.45% | -1.28% |
Quarter on quarter
- Revenue, quarter on quarter
- +3.7%
- Net profit, quarter on quarter
- +15.3%
- Operating margin, quarter on quarter
- +59 bps
Disclosure profile 27 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Contract / MoU | 3 |
| Acquisition | 1 |
| Concall Transcript | 1 |
| Credit Rating | 1 |
| Investor Presentation | 1 |
| Press Release | 1 |
| Restructuring | 1 |
| Results | 1 |
| Selected sub-total | 10 |
| Procedural | |
| Analyst / Investor Meet | 5 |
| AGM / EGM | 2 |
| General | 2 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Monitoring Agency | 1 |
| Outcome | 1 |
| PIT / Insider Policy | 1 |
| SAST | 1 |
| Subsidiary Incorporation | 1 |
| Trading Window | 1 |
| Procedural sub-total | 17 |
| Total | 27 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
27 filings · 10 selected · busiest 2026-08-11
Filing rhythm · the twelve most recent
2026-08-172026-10-07
SelectedProcedural
Filings
27 in the window · 17 earlier on record
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith a certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for quarter ended 30th September, 2026 received from M/s. KFIN Technologies Limited.
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
28 September 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Polar Capital Funds PLC
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
25 September 2026 ·
Closure of Trading Window
Trading window shall be closed till 48 hours from the declaration of Unaudited Financial Results of the Company for the quarter and half yearly ended September 30, 2026.
Insider Trading / SAST / Closure of Trading Window View filing →
-
22 September 2026 ·
Analyst / Investor Meet - Intimation
Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.
Company Update / Analyst / Investor Meet View filing →
-
18 September 2026 ·
Credit Rating
Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform the update on Credit Ratings of the Company received from India Ratings and Research Private Limited as per the disclosure ....
Company Update / Credit Rating View filing →
-
18 September 2026 ·
Restructuring
Disclosure under Reg 30 of SEBI Listing Regulations -Rationalisation and Consolidation of Company's Step-down Subsidiaries in the Philippines as per the disclosure annexed herewith.
Company Update / Restructuring View filing →
-
14 September 2026 ·
Memorandum of Understanding /Agreements
Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform you that Nephrocare Health Services, Philippines Inc., a step-down wholly owned subsidiary of the Company has acquired a ....
Company Update / Memorandum of Understanding /Agreements View filing →
-
3 September 2026 ·
Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Grant Of Esops Under The Nephroplus Employee Stock Option Scheme 2026.
We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith.
Company Update / General View filing →
-
1 September 2026 ·
Acquisition
Pursuant to Reg 30 of SEBI Listing Regulations, we wish to hereby inform that NephroPlus Health Services Kazakhstan LLP, an overseas subsidiary of the Company has entered into a Share Purchase ....
Company Update / Acquisition View filing →
-
31 August 2026 ·
Disclosure Under Regulation 30 Of SEBI Listing Regulations
Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform that the Company has received Tax demand pursuant to Tax Audit as per the annexed disclosure.
Company Update / General View filing →
-
19 August 2026 ·
Earnings Call Transcript
Please find enclosed herewith Transcripts for the investors Earning call held on August 12, 2026.
Company Update / Earnings Call Transcript View filing →
-
17 August 2026 ·
Memorandum of Understanding /Agreements
Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform that Nephrocare Health Services, Phillipines Inc., a step-down wholly-owned subsidiary of the Company has acquired a dialysis ....
Company Update / Memorandum of Understanding /Agreements View filing →
-
13 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Declartion of voting results along with scrutinizers report of the 17th AGM of the Company.
AGM/EGM / AGM View filing →
-
13 August 2026 ·
Analyst / Investor Meet - Intimation
Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.
Company Update / Analyst / Investor Meet View filing →
-
13 August 2026 ·
Memorandum of Understanding /Agreements
Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform that Nephrocare Health Services, Phillipines Inc., an overseas stepdown wholly-owned subsidiary of the Company has acquired ....
Company Update / Memorandum of Understanding /Agreements View filing →
-
12 August 2026 ·
Updates on Acquisition
Clarification to disclosure under Reg 30 dated May 26, 2026 regarding incorporation of Nephrocare Services Kazakhstan LLP.
Company Update / Acquisition View filing →
-
12 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Summary of proceedings of the 17th AGM of the Company.
AGM/EGM / AGM View filing →
-
12 August 2026 ·
Analyst / Investor Meet - Outcome
In Continuation to our letter dated July 24, 2026 please find enclosed link of the audio recording of the Investors' Conference Call held on August 12, 2026 on the Unaudited Standalone ....
Company Update / Analyst / Investor Meet View filing →
-
11 August 2026 ·
Monitoring Agency Report
Pursuant to Reg 32 of SEBI Listing Regulations, read with Reg 41 of SEBI ICDR Regulations, please find enclosed herewith Monitoring Agency Report for quarter ended June 30, 2026.
Company Update / Monitoring Agency Report View filing →
-
11 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Held On August 11, 2026.
Please find attached the outcome of Board meeting held on August 11, 2026.
Others / Outcome without intimation View filing →
-
11 August 2026 ·
Press Release / Media Release
Press release on Un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.
Company Update / Press Release / Media Release View filing →
-
11 August 2026 ·
Investor Presentation
Please find attached investor presentation for quarter ended June 30, 2026.
Company Update / Investor Presentation View filing →
-
11 August 2026 ·
Financial Results For The Quarter Ended June 30, 2026
Un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.
Result / Financial Results View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
Trading Plan under SEBI (PIT) Regulations, 2015
Please find enclosed the Trading Plans dated August 05, 2026 received from Designated Persons of the company and same have been approved by the compliance officer.
Company Update / Trading Plan under SEBI (PIT) Regulations, 2015 View filing →
-
24 July 2026 ·
Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Result Conference Call on Wednesday, 12th August, 2026 at 10:00 ....
Company Update / Analyst / Investor Meet View filing →
-
24 July 2026 ·
Board Meeting Intimation for The Company Has Informed BSE That The Meeting Of The Board Of Directors Is Scheduled On 11/08/2026 ,Inter Alia, To Consider And Approve The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Nephrocare Health Services Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11-08-2026 ,inter alia, to consider and approve the Unaudited Standalone ....
Board Meeting / Board Meeting View filing →
RSS feed for Nephrocare Health Services Ltd · the 50 most recent filings